What’s Next? Five Things To Look Out For In January
Amgen’s Rituximab Biosimilar Set For Commercial Launch
A third biosimilar to Genentech’s Rituxan is set to hit the US this month, as players begin to publish full-year financial results encompassing a remarkable year.
